Shots:

• The P-III study involves assessing of SCB-808 (SC) vs Enbrel (SC) in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) to evaluate its safety- efficacy and PK
• The company utilizes its Trimer-Tag technology platform to develop novel therapies targeting trimerization-dependent pathways and is also leveraging its cGMP biomanufacturing capabilities to develop biosimilars
• SCB-808 is mAb being developed as a prefilled syringe ready-for-injection self-administered for the treatment of rheumatoid arthritis and other autoimmune diseases

Click here to read full press release/ article | Ref: GlobeNewswire| Image: Signbox